# OnCo record paper-mavoric-mogamulizumab-lancet-oncol-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-mavoric-mogamulizumab-lancet-oncol-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-mavoric-mogamulizumab-lancet-oncol-2018" ;
  schema:name "MAVORIC: mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma"@en ;
  schema:description "The anti-CCR4 antibody mogamulizumab doubled the time to progression compared with vorinostat in previously treated mycosis fungoides and Sezary syndrome, with particularly strong activity in the blood, and became the first antibody approved for these lymphomas."@en ;
  schema:url <https://onco.cc/key-papers/paper-mavoric-mogamulizumab-lancet-oncol-2018/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(18)30379-6>, <https://pubmed.ncbi.nlm.nih.gov/30100375/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(18)30379-6> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "Kim YH, Bagot M, Pinter-Brown L, et al." ;
  onco:cancers <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/mogamulizumab/>, <https://onco.cc/drugs/vorinostat/> ;
  onco:trials <https://onco.cc/trials/mavoric/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .